Who
Jane Wright-Mitchell
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Vera Therapeutics; General Counsel, Vaxcyte; Chief Legal Officer, Talphera.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $526K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 24 Jul 2014
- Last trade
- 23 Mar 2026
- Last filed
- 25 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Mar 2026filed 25 Mar 2026 | VERA Vera TherapeuticsBiotechnology | SEC FORM 4 Code A | —42,403 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,850 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,850 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | VERA Vera TherapeuticsBiotechnology | SEC FORM 4 Code A | —42,403 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $5,0752,500 at $2.03 | filing |
| 16 Aug 2021filed 18 Aug 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $65K2,500 at $26.00 | filing |
| 12 Aug 2021filed 16 Aug 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $20K10,000 at $2.03 | filing |
| 12 Aug 2021filed 16 Aug 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $260K10,000 at $26.00 | filing |
| 12 Aug 2021filed 16 Aug 2021 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 1 Apr 2021filed 6 Apr 2021 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,340 at $0.00 | filing |
| 15 Mar 2021filed 17 Mar 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $5,0752,500 at $2.03 | filing |
| 15 Mar 2021filed 17 Mar 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $27K1,013 at $27.01 | filing |
| 15 Mar 2021filed 17 Mar 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $41K1,487 at $27.49 | filing |
| 15 Mar 2021filed 17 Mar 2021 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 16 Feb 2021filed 17 Feb 2021 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 16 Feb 2021filed 17 Feb 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $5,0752,500 at $2.03 | filing |
| 16 Feb 2021filed 17 Feb 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $67K2,500 at $26.95 | filing |
| 15 Jan 2021filed 19 Jan 2021 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 15 Jan 2021filed 19 Jan 2021 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $5,0752,500 at $2.03 | filing |
News
Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program AdvancesPCVX · rttnews.com · 16 Oct 2026Vaxcyte's (PCVX) Overweight Rating Reaffirmed at Cantor FitzgeraldPCVX · dailypolitical.com · 13 Oct 2026Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase on Analyst UpgradePCVX · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Jane Wright-Mitchell; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.